• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Sources of variation in studies of the early bactericidal activity of antituberculosis drugs.

作者信息

Sirgel F, Venter A, Mitchison D

机构信息

National Tuberculosis Research Programme, Medical Research Council, PO Box 19070, Tygerberg, 7505 South Africa.

出版信息

J Antimicrob Chemother. 2001 Feb;47(2):177-82. doi: 10.1093/jac/47.2.177.

DOI:10.1093/jac/47.2.177
PMID:11157902
Abstract

The early bactericidal activity (EBA) of antituberculosis drugs can be measured as the daily fall in cfu counts of Mycobacterium tuberculosis in sputum, usually during the first 2 days of treatment. In studies of low potency drugs, it is necessary to compare the treated group of patients with a group who receives no chemotherapy (Nil group). Over the past 10 years, five Nil groups of between five and 13 patients have been studied in Cape Town and two Nil groups in Hong Kong. There was a suggestion of an increase in variation within the Cape Town groups, as shown by a regression of variance size against study date (P = 0.06), which could not be attributed to technical causes. It might indicate increasing host resistance in the Western Cape epidemic of tuberculosis. Since the weighted mean of all Nil groups at Cape Town was 0.00036, very close to zero, it would seem safe to test means of treated groups against zero thus increasing precision and avoiding ethical problems in delaying treatment. In contrast to Nil groups, the variation found in five groups who received 300 mg isoniazid daily (INH 300) was uniform and homoscedastic, possibly because the additional variation was caused mainly by individual differences in plasma isoniazid concentrations and patient body weights. The mean EBA in the INH 300 series was 0.575 with 95% confidence limits of 0.515 and 0.636.

摘要

相似文献

1
Sources of variation in studies of the early bactericidal activity of antituberculosis drugs.
J Antimicrob Chemother. 2001 Feb;47(2):177-82. doi: 10.1093/jac/47.2.177.
2
A multicentre study of the early bactericidal activity of anti-tuberculosis drugs.一项抗结核药物早期杀菌活性的多中心研究。
J Antimicrob Chemother. 2000 Jun;45(6):859-70. doi: 10.1093/jac/45.6.859.
3
Time Trends in Sputum Mycobacterial Load and Two-Day Bactericidal Activity of Isoniazid-Containing Antituberculosis Therapies.含异烟肼抗结核治疗的痰液分枝杆菌载量及两日杀菌活性的时间趋势
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.02088-16. Print 2017 Apr.
4
The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis.利福布汀对香港肺结核患者痰菌活菌计数的早期杀菌活性。
Tuber Lung Dis. 1992 Feb;73(1):33-8. doi: 10.1016/0962-8479(92)90077-W.
5
Early bactericidal activity of antituberculosis agents.抗结核药物的早期杀菌活性。
Expert Rev Anti Infect Ther. 2003 Jun;1(1):141-55. doi: 10.1586/14787210.1.1.141.
6
Time to liquid culture positivity can substitute for colony counting on agar plates in early bactericidal activity studies of antituberculosis agents.液体培养阳性时间可以替代琼脂平板上的菌落计数,用于抗结核药物早期杀菌活性研究。
Clin Microbiol Infect. 2012 Jul;18(7):711-7. doi: 10.1111/j.1469-0691.2011.03626.x. Epub 2011 Aug 18.
7
The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment.通过痰液活菌计数测定利福布汀在肺结核患者中的早期杀菌活性:一种新的药物评估方法。
J Antimicrob Chemother. 1993 Dec;32(6):867-75. doi: 10.1093/jac/32.6.867.
8
Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis.乙胺丁醇、吡嗪酰胺以及异烟肼、利福平与吡嗪酰胺固定复方制剂(卫非特)对肺结核患者的早期杀菌活性。
S Afr Med J. 1996 Feb;86(2):155-8.
9
A reiterative method for calculating the early bactericidal activity of antituberculosis drugs.一种计算抗结核药物早期杀菌活性的迭代方法。
Am J Respir Crit Care Med. 2002 Jul 1;166(1):31-5. doi: 10.1164/rccm.2112077.
10
Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis.莫西沙星与异烟肼联合用药对涂片阳性肺结核的早期杀菌活性
J Antimicrob Chemother. 2005 Dec;56(6):1169-71. doi: 10.1093/jac/dki376. Epub 2005 Oct 13.

引用本文的文献

1
Clinically encountered growth phenotypes of tuberculosis-causing bacilli and their study: A review.临床遇到的结核分枝杆菌生长表型及其研究:综述。
Front Cell Infect Microbiol. 2022 Nov 10;12:1029111. doi: 10.3389/fcimb.2022.1029111. eCollection 2022.
2
Flow cytometry method for absolute counting and single-cell phenotyping of mycobacteria.流式细胞术绝对计数和分枝杆菌单细胞表型分析方法。
Sci Rep. 2021 Sep 20;11(1):18661. doi: 10.1038/s41598-021-98176-5.
3
Drug Effect of Clofazimine on Persisters Explains an Unexpected Increase in Bacterial Load in Patients.
氯法齐明对持留菌的药物作用解释了患者细菌载量的意外增加。
Antimicrob Agents Chemother. 2020 Apr 21;64(5). doi: 10.1128/AAC.01905-19.
4
Modeling and Simulation of Pretomanid Pharmacodynamics in Pulmonary Tuberculosis Patients.肺结核患者中普瑞曼尼药效学的建模与模拟
Antimicrob Agents Chemother. 2019 Sep 9;63(12). doi: 10.1128/AAC.00732-19. Epub 2019 Sep 30.
5
A model-informed preclinical approach for prediction of clinical pharmacodynamic interactions of anti-TB drug combinations.一种基于模型的临床前方法,用于预测抗结核药物组合的临床药效学相互作用。
J Antimicrob Chemother. 2018 Feb 1;73(2):437-447. doi: 10.1093/jac/dkx380.
6
Application of the Multistate Tuberculosis Pharmacometric Model in Patients With Rifampicin-Treated Pulmonary Tuberculosis.多状态结核病药代动力学模型在利福平治疗的肺结核患者中的应用。
CPT Pharmacometrics Syst Pharmacol. 2016 May;5(5):264-73. doi: 10.1002/psp4.12079. Epub 2016 May 17.
7
Assessment of treatment response in tuberculosis.结核病治疗反应的评估
Expert Rev Respir Med. 2016 Jun;10(6):643-54. doi: 10.1586/17476348.2016.1166960. Epub 2016 Mar 31.
8
Differences in EBA in the first two days of standard anti-tuberculosis treatment in different geographic regions.不同地理区域标准抗结核治疗前两天内的血沉棕黄层抗体差异。
Int J Tuberc Lung Dis. 2014 Aug;18(8):1006-7. doi: 10.5588/ijtld.13.0826.
9
Alternative strategies for proof-of-principle studies of antibacterial agents.抗菌剂原理验证研究的替代策略。
Antimicrob Agents Chemother. 2014 Aug;58(8):4257-63. doi: 10.1128/AAC.02473-14. Epub 2014 May 27.
10
Assessment of the Efficacy of New Anti-Tuberculosis Drugs.新型抗结核药物疗效评估
Open Infect Dis J. 2008 Dec;2:59-76. doi: 10.2174/1874279300802010059.